References
- Abell TL, Bernstein RK, Cutts T, Farrugia G, Forster J, Hasler WL, McCallum RW, Olden KW, Parkman HP, Parrish CR, et al. Treatment of gastroparesis: A multidisciplinary clinical review. Neurogastroenterology and Motility 2006; 18(4)263–283
- Bakke OM, Segura J. The absorption and elimination of metoclopramide in three animal species. Journal of Pharmacy and Pharmacology 1976; 28(1)32–39
- Bateman DN. Clinical pharmacokinetics of metoclopramide. Clinical Pharmacokinetics 1983; 8(6)523–529
- Brunton L, Lazo J, Parker K. Goodman and Gilman's the pharmacological basis of therapeutics. McGraw-Hill, New York, NY 2005
- Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes morphine glucuronidation. Drug Metabolism and Disposition 1997; 25(1)1–4
- Cornish-Bowden A. A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors. Biochemistry Journal 1974; 137(1)143–144
- Cowan A, Earnest DL, Ligozio G, Rojavin MA. Omeprazole-induced slowing of gastrointestinal transit in mice can be countered with tegaserod. European Journal of Pharmacology 2005; 517(1–2)127–131
- Desta Z, Wu GM, Morocho AM, Flockhart DA. The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metabolism and Disposition 2002; 30(3)336–343
- Fisher MB, Campanale K, Ackermann BL, VandenBranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethicin. Drug Metabolism and Disposition 2000; 28(5)560–566
- Kamerman PR, Becker N, Fick LG. Interactions between metoclopramide and morphine: Enhanced antinociception and motor dysfunction in rats. Clinical and Experimental Pharmacology and Physiology 2007; 34(1–2)106–112
- Krenn H, Jellinek H, Haumer H, Oczenski W, Fitzgerald R. Naloxone-resistant respiratory depression and neurological eye symptoms after intrathecal morphine. Anesthetics and Analgesics 2000; 91(2)432–433
- Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Court MH. Validation of serotonin (5-hydroxytryptamine) as an in vitro substrate probe for human UDP-glucuronosyltransferase (UGT) 1A6. Drug Metabolism and Disposition 2003; 31: 133–139
- Kuo CK, Hanioka N, Hoshikawa Y, Oguri K, Yoshimura H. Species difference of site-selective glucuronidation of morphine. Journal of Pharmacobiodynamics 1991; 14(4)187–193
- Lear L, Nation RL, Stupans I. Influence of morphine concentration on detergent activation of rat liver morphine-UDP-glucuronosyltransferase. Biochemistry and Pharmacology 1991; 42(Suppl.)S55–S60
- Leucuta SE, Vlase L. Pharmacokinetics and metabolic drug interactions. Current Clinical Pharmacology 2006; 1: 5–20
- Nagar S, Remmel RP, Hebbel RP, Zimmerman CL. Metabolism of opioids is altered in liver microsomes of sickle cell transgenic mice. Drug Metabolism and Disposition 2004; 32(1)98–104
- O’Leary KA, De Pascual-Tereasa S, Needs PW, Bao YP, O’Brien NM, Williamson G. Effect of flavonoids and vitamin E on cyclooxygenase-2 (COX-2) transcription. Mutation Research 2004; 551(1–2)245–254
- Park MI, Camilleri M. Gastroparesis: Clinical update. American Journal of Gastroenterology 2006; 101(5)1129–1139
- Pleuvry BJ. Pharmacodynamic and pharmacokinetic drug interactions. Anaesthesia and Intensive Care Medicine 2005; 6(4)129–133
- Segel IH. Enzyme kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley, New York, NY 1993
- Soars MG, Ring BJ, Wrighton SA. The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metabolism and Disposition 2003; 31(6)762–767
- Suchitra AD, Dkhar SA, Shewade DG, Shashindran CH. Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice. World Journal of Gastroenterology 2003; 9(4)779–783
- Tomizawa M, Cowan A, Casida JE. Analgesic and toxic effects of neonicotinoid insecticides in mice. Toxicology and Applied Pharmacology 2001; 177(1)77–83
- Yu J, Paine MJ, Marechal JD, Kemp CA, Ward CJ, Brown S, Sutcliffe MJ, Roberts GC, Rankin EM, Wolf CR. In silico prediction of drug binding to CYP2D6: Identification of a new metabolite of metoclopramide. Drug Metabolism and Disposition 2006; 34(8)1386–1392
- Zarrindast MR, Dinkoub Z, Homayoun H, Bakhtiarian A, Khavandgar S. Dopamine receptor mechanism(s) and morphine tolerance in mice. Journal of Psychopharmacology 2002; 16(3)261–266
- Zarrindast MR, Nassiri-Rad S, Pazouki M. Effects of dopaminergic agents on antinociception in formalin test. Genetics and Pharmacology 1999; 32(4)517–522